Candel Therapeutics Reports Positive Mid-Stage Trial Results for CAN-2409
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CADL?
Source: seekingalpha
- Survival Rate Improvement: Candel Therapeutics reported that in its ongoing Phase 2a trial, 50% of patients receiving CAN-2409 combination therapy were alive at 24 months, a significant increase from the previous 39%, indicating the lasting antitumor effects of the therapy.
- Trial Design: The open-label trial was designed to evaluate the efficacy of aglatimagene combined with valacyclovir and PD-((L))1 checkpoint inhibitors in patients with advanced non-small cell lung cancer who did not adequately respond to PD-((L))1 therapy, showcasing promising clinical outcomes.
- Future Plans: Candel plans to expand the program into a pivotal Phase 3 trial focusing on non-squamous histology NSCLC, with trial initiation expected in Q2 2026, aiming to further validate the efficacy of its therapy.
- Market Reaction: Following the announcement of positive trial results, Candel's stock traded higher on Tuesday, reflecting investor optimism regarding the potential of its immunotherapy, which may attract further investment and attention.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.990
Low
7.00
Averages
18.33
High
25.00
Current: 4.990
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Candel Therapeutics Reports Positive Mid-Stage Trial Results for CAN-2409
- Survival Rate Improvement: Candel Therapeutics reported that in its ongoing Phase 2a trial, 50% of patients receiving CAN-2409 combination therapy were alive at 24 months, a significant increase from the previous 39%, indicating the lasting antitumor effects of the therapy.
- Trial Design: The open-label trial was designed to evaluate the efficacy of aglatimagene combined with valacyclovir and PD-((L))1 checkpoint inhibitors in patients with advanced non-small cell lung cancer who did not adequately respond to PD-((L))1 therapy, showcasing promising clinical outcomes.
- Future Plans: Candel plans to expand the program into a pivotal Phase 3 trial focusing on non-squamous histology NSCLC, with trial initiation expected in Q2 2026, aiming to further validate the efficacy of its therapy.
- Market Reaction: Following the announcement of positive trial results, Candel's stock traded higher on Tuesday, reflecting investor optimism regarding the potential of its immunotherapy, which may attract further investment and attention.
See More
Candel Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Candel Therapeutics reported a GAAP EPS of -$0.54 for Q4 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $119.7 million, up from $102.7 million as of December 31, 2024, reflecting improvements in cash management.
- Funding Outlook: Based on current operating plans, the company expects its existing cash and cash equivalents, along with proceeds from the follow-on equity offering in February 2026, to fund operations into Q1 2028, demonstrating confidence in future liquidity.
- Stock Offering Plan: Candel Therapeutics is launching a $100 million public stock offering; while this may lead to a decline in share price, it provides essential funding to meet future operational needs.
See More
Candel Therapeutics Announces Public Offering Pricing
- Public Offering Pricing: Candel Therapeutics has priced an underwritten public offering of approximately 18.35 million shares at $5.45 per share, aiming to raise about $100 million to support critical launch readiness and ongoing development costs for its cancer therapies.
- Clear Use of Proceeds: The funds will be allocated towards the launch readiness of its lead product candidate, aglatimagene besadenovec (CAN-2409), and ongoing development for its phase 3 trial in non-small cell lung cancer (NSCLC), highlighting the company's commitment to advancing its viral immunotherapy pipeline.
- Weak Stock Performance: Candel's shares fell 11.43% to $5.27 during premarket trading, trading 10.4% below its 20-day and 50-day simple moving averages, indicating bearish market sentiment surrounding the stock.
- Optimistic Analyst Ratings: Despite the stock's decline, it maintains a Buy rating with an average price target of $15.77, reflecting analysts' confidence in the company's future growth, particularly given the positive clinical trial results for its product candidate.
See More
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
Candel Therapeutics Prices $100 Million Share Offering
- Share Offering Pricing: Candel Therapeutics has priced 18.35 million common shares at $5.45 each, aiming to raise $100 million, although the stock fell 11.76% to $5.25, indicating a negative market reaction to the offering.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to critical launch readiness, medical affairs, and commercialization activities for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer, as well as ongoing phase 3 trial costs for non-small cell lung cancer, demonstrating the company's commitment to oncology.
- Significant Clinical Progress: Candel recently completed successful phase 2a trials of aglatimagene in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is conducting a phase 3 trial in localized prostate cancer, showcasing the potential of its lead product candidate.
- FDA Accelerated Approvals: The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to aglatimagene for newly diagnosed localized prostate cancer, Fast Track for NSCLC, and both Fast Track and Orphan Drug Designations for PDAC, enhancing its competitive edge and commercialization prospects.
See More
Candel Therapeutics Prices $100M Public Offering
- Offering Size: Candel Therapeutics has announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, although actual revenue may decrease after underwriting discounts and other expenses.
- Closing Timeline: The offering is expected to close on or about February 23, 2026, subject to customary closing conditions, which may impact the company's liquidity and short-term financial health.
- Market Reaction: Following the announcement of the offering, Candel Therapeutics' stock price has declined, reflecting market concerns regarding the company's future growth potential, which could affect investor confidence.
- Strategic Implications: This offering will provide Candel with funding to support its R&D projects; despite the negative market reaction, successful financing will help the company maintain operations and innovation capabilities in the competitive biopharmaceutical industry.
See More
Candel Therapeutics Reports Positive Mid-Stage Trial Results for CAN-2409
- Survival Rate Improvement: Candel Therapeutics reported that in its ongoing Phase 2a trial, 50% of patients receiving CAN-2409 combination therapy were alive at 24 months, a significant increase from the previous 39%, indicating the lasting antitumor effects of the therapy.
- Trial Design: The open-label trial was designed to evaluate the efficacy of aglatimagene combined with valacyclovir and PD-((L))1 checkpoint inhibitors in patients with advanced non-small cell lung cancer who did not adequately respond to PD-((L))1 therapy, showcasing promising clinical outcomes.
- Future Plans: Candel plans to expand the program into a pivotal Phase 3 trial focusing on non-squamous histology NSCLC, with trial initiation expected in Q2 2026, aiming to further validate the efficacy of its therapy.
- Market Reaction: Following the announcement of positive trial results, Candel's stock traded higher on Tuesday, reflecting investor optimism regarding the potential of its immunotherapy, which may attract further investment and attention.
See More
Candel Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Candel Therapeutics reported a GAAP EPS of -$0.54 for Q4 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $119.7 million, up from $102.7 million as of December 31, 2024, reflecting improvements in cash management.
- Funding Outlook: Based on current operating plans, the company expects its existing cash and cash equivalents, along with proceeds from the follow-on equity offering in February 2026, to fund operations into Q1 2028, demonstrating confidence in future liquidity.
- Stock Offering Plan: Candel Therapeutics is launching a $100 million public stock offering; while this may lead to a decline in share price, it provides essential funding to meet future operational needs.
See More
Candel Therapeutics Announces Public Offering Pricing
- Public Offering Pricing: Candel Therapeutics has priced an underwritten public offering of approximately 18.35 million shares at $5.45 per share, aiming to raise about $100 million to support critical launch readiness and ongoing development costs for its cancer therapies.
- Clear Use of Proceeds: The funds will be allocated towards the launch readiness of its lead product candidate, aglatimagene besadenovec (CAN-2409), and ongoing development for its phase 3 trial in non-small cell lung cancer (NSCLC), highlighting the company's commitment to advancing its viral immunotherapy pipeline.
- Weak Stock Performance: Candel's shares fell 11.43% to $5.27 during premarket trading, trading 10.4% below its 20-day and 50-day simple moving averages, indicating bearish market sentiment surrounding the stock.
- Optimistic Analyst Ratings: Despite the stock's decline, it maintains a Buy rating with an average price target of $15.77, reflecting analysts' confidence in the company's future growth, particularly given the positive clinical trial results for its product candidate.
See More
U.S. Stock Futures Rise as Market Awaits GDP Data Release
- Market Sentiment Rebounds: U.S. stock futures rose after closing lower on Thursday, with all major benchmark indices showing positive trends, indicating investor anticipation for the upcoming fourth-quarter GDP data that could influence future monetary policy.
- Stable Rate Expectations: The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March, providing some stability to the market despite ongoing inflation pressures.
- Divergent Stock Performances: Copart Inc. (NASDAQ: CPRT) dropped 6.64% following disappointing second-quarter earnings, while Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after reporting better-than-expected financial results, reflecting varied market reactions to company fundamentals.
- Analyst Optimism: Scott Wren from Wells Fargo upgraded the U.S. GDP growth forecast from 2.4% to 2.9%, and despite increased market volatility, he recommends investors focus on sectors like Financials and Industrials that benefit from economic growth, viewing current dips as opportunities to enter large- and mid-cap stocks.
See More
Candel Therapeutics Prices $100 Million Share Offering
- Share Offering Pricing: Candel Therapeutics has priced 18.35 million common shares at $5.45 each, aiming to raise $100 million, although the stock fell 11.76% to $5.25, indicating a negative market reaction to the offering.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated to critical launch readiness, medical affairs, and commercialization activities for aglatimagene besadenovec (CAN-2409) in early localized prostate cancer, as well as ongoing phase 3 trial costs for non-small cell lung cancer, demonstrating the company's commitment to oncology.
- Significant Clinical Progress: Candel recently completed successful phase 2a trials of aglatimagene in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is conducting a phase 3 trial in localized prostate cancer, showcasing the potential of its lead product candidate.
- FDA Accelerated Approvals: The FDA has granted Fast Track and Regenerative Medicine Advanced Therapy Designations to aglatimagene for newly diagnosed localized prostate cancer, Fast Track for NSCLC, and both Fast Track and Orphan Drug Designations for PDAC, enhancing its competitive edge and commercialization prospects.
See More
Candel Therapeutics Prices $100M Public Offering
- Offering Size: Candel Therapeutics has announced a public offering of 18,348,624 shares at a price of $5.45 per share, with expected gross proceeds of $100 million, although actual revenue may decrease after underwriting discounts and other expenses.
- Closing Timeline: The offering is expected to close on or about February 23, 2026, subject to customary closing conditions, which may impact the company's liquidity and short-term financial health.
- Market Reaction: Following the announcement of the offering, Candel Therapeutics' stock price has declined, reflecting market concerns regarding the company's future growth potential, which could affect investor confidence.
- Strategic Implications: This offering will provide Candel with funding to support its R&D projects; despite the negative market reaction, successful financing will help the company maintain operations and innovation capabilities in the competitive biopharmaceutical industry.
See More
